NASDAQ:FATE - Fate Therapeutics Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$14.34 -0.08 (-0.55 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$14.42
Today's Range$14.13 - $14.70
52-Week Range$8.35 - $17.98
Volume307,400 shs
Average Volume651,209 shs
Market Capitalization$926.41 million
P/E Ratio-14.06
Dividend YieldN/A

Analyst Ratings

Fate Therapeutics (NASDAQ:FATE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. Their average twelve-month price target is $18.8571, suggesting that the stock has a possible upside of 31.50%. The high price target for FATE is $23.00 and the low price target for FATE is $12.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.782.89
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $18.8571$18.5714$18.5714$16.7143
Price Target Upside: 31.50% upside37.80% upside25.91% upside64.35% upside

Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History

Price Target History for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/11/2019WedbushBoost Price TargetOutperform ➝ Outperform$19.00 ➝ $21.00LowView Rating Details
1/3/2019StephensDowngradeOverweight ➝ EqualMediumView Rating Details
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$17.00LowView Rating Details
9/25/2018Piper Jaffray CompaniesReiterated RatingOverweight$23.00HighView Rating Details
8/7/2018HC WainwrightReiterated RatingHold$12.00HighView Rating Details
8/1/2018CitigroupInitiated CoverageBuy$20.00HighView Rating Details
3/6/2018UBS GroupDowngradeOutperform ➝ Market PerformHighView Rating Details
3/6/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $20.00HighView Rating Details
3/6/2018Wells Fargo & CoReiterated RatingOutperform$10.00 ➝ $19.00HighView Rating Details
12/12/2017Raymond JamesReiterated RatingBuyMediumView Rating Details
9/8/2017Leerink SwannReiterated RatingOutperform ➝ Outperform$7.00MediumView Rating Details
3/18/2017Roth CapitalSet Price TargetBuy$8.00LowView Rating Details
(Data available from 2/20/2017 forward)
This page was last updated on 2/20/2019 by Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel